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Incidence of malaria by cotrimoxazole use in
HIV-infected Ugandan adults on antiretroviral
therapy: a randomised, placebo-controlled study
Ronnie P. Kasiryea,b, Kathy Baisleyb, Paula Munderia, Jonathan Levina,c,
Zacchaeus Anywainea, Andrew Nunnd, Anatoli Kamalia
and Heiner Grosskurthb
Introduction: Previous unblinded trials have shown increased malaria among
HIV-infected adults on antiretroviral therapy (ART) who stop cotrimoxazole (CTX)
prophylaxis. We investigated the effect of stopping CTX on malaria in HIV-infected
adults on ART in a double-blind, placebo-controlled trial.
Methods: HIV-infected Ugandan adults stable on ART and CTX with CD4þ cell count
at least 250 cells/ml were randomized (1 : 1) to continue CTX or stop CTX and receive
matching placebo (COSTOP trial; ISRCTN44723643). Clinical malaria was defined as
fever and a positive blood slide, and considered severe if a participant had at least one
clinical or laboratory feature of severity or was admitted to hospital. Malaria incidence
and rate ratios were estimated using random effects Poisson regression, accounting for
multiple episodes.
Results: A total of 2180 participants were enrolled and followed for a median of
2.5 years; 453 malaria episodes were recorded. Malaria incidence was 9.1/100 person-
years (pyrs) [95% confidence interval (CI)¼8.2–10.1] and was higher on placebo
(rate ratio 3.47; CI¼2.74–4.39). Malaria in the placebo arm decreased over time;
although incidence remained higher than in the CTX arm, the difference between arms
reduced slightly (interaction P value¼0.10). Fifteen participants experienced severe
malaria (<1%); overall incidence was 0.30/100 pyrs (CI¼0.18–0.49). There was one
malaria-related death (CTX arm).
Conclusion: HIV-infected adults – who are stable on ART and stop prophylactic CTX –
experience more malaria than those that continue, but this difference is less than has
been reported in previous trials. Few participants had severe malaria. Further research
might be useful in identifying groups that can safely stop CTX prophylaxis.
Copyright  2016 Wolters Kluwer Health, Inc. All rights reserved.
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Introduction
Adults with advanced HIV disease who are not on
antiretroviral therapy (ART) are at an increased risk of
opportunistic infections and malaria [1–3]. Cotrimoxazole
(CTX), an antimicrobial agent containing trimethoprim
and sulfamethoxazole, reduces the incidence of opportu-
nistic infections, mortality and malaria [4–9]. However,
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CTX use is associated with increases in cost of care [10],
risk of haematological toxicity [11], hypersensitivity skin
reactions [12] and pill burden. Once started on ART,
patients’ immune function improves and the risk of
opportunistic infections reduces. Based on studies from
developed countries it has been recommended to stop
CTX once patients’ immune function has been restored
[13,14]; however, this may not be advisable for sub-Saharan
Africa where the prevalence of malaria and bacterial
infections is often high. Of recent, WHO recommends
that CTX may be discontinued in patients who are
clinically stable with evidence of immune recovery and/or
viral suppression on ART, but should be continued in
countries with high endemicity of malaria and bacterial
infections [15]. A systematic literature review found that
patients who stop CTX prophylaxis experience an increase
in malaria episodes, with the strongest evidence provided
by randomized-controlled trials (RCTs); however, none of
the reported RCTs was blinded so observational or
reporting bias cannot be excluded [16]. We investigated the
effect of CTX in a blinded, placebo-controlled trial on
CTX cessation in HIV-infected adults who are stable on
ART (COSTOP; ISRCTN44723643). The main results
of this trial have been reported previously. In summary,
the trial found that stopping CTX prophylaxis leads
to a significant increase in CTX-preventable clinical
events [mainly bacterial pneumonias; adjusted hazard ratio
(aHR)¼ 1.57, 90% confidence interval (CI)¼ 1.12–2.21]
and a significant decrease in grade 3/4 haematological
adverse events (aHR¼ 0.70, 95%CI¼ 0.59–0.82), the co-
primary outcomes of the trial. There was no effect on
all-cause mortality. The estimated number needed to treat
(NNT) for 1 year to prevent one infection (excluding
malaria) was 113 [17]. In this article we provide a detailed
account on the effect of CTX prophylaxis on malaria, a
secondary outcome of the trial.
Methods
COSTOP was a randomized, double-blind, placebo-
controlled noninferiority trial conducted in Uganda to
determine whether long-term prophylaxis with CTX can
be safely discontinued among HIV-infected adults on
ART with sustained immune competence (defined as
CD4þ cell counts 250 cells/ml) [17,18]. The trial had
two co-primary outcomes: time to occurrence of the first
CTX-preventable clinical event (according to a pre-
defined list) or death, and time to the occurrence of the
first grade 3 or 4 haematological adverse event [17].
COSTOP was conducted by the MRC/UVRI Uganda
Research Unit on AIDS (MRC/UVRI) at its research
clinics in Masaka and Entebbe in Uganda.
Study procedures
Detailed procedures have been described previously [18].
Briefly, participants were eligible for enrolment if they
were HIV infected; aged 18–59 years; clinically
asymptomatic; had been taking CTX and ART for
at least 6 months; had two CD4þ cell counts not less
than 250 cells/ml, the most recent within 4 weeks of
enrolment; and were able to attend regular study
appointments. Exclusion criteria included pregnancy,
grade 3 or 4 anaemia, neutropenia or thrombocytopenia.
At an initial screening visit, information was recorded on
socio-demographics, medical history, current illness and
medication and a physical examination was performed.
Laboratory tests included a full blood count, malaria slide
and CD4þ cell count.
At enrolment (2–4 weeks after screening), participants
were randomized to receive either active CTX (960 mg)
or matching placebo once daily in place of their regular
CTX. Randomization was stratified by enrolment site
and CD4þ cell count (250–499 and 500 cells/ml).
Participants were provided with an insecticide-treated
bed net (ITN) and educated about the importance of
using it. Participants continued to receive ART from their
usual providers, but trial staff monitored ART availability
to ensure an uninterrupted supply. Enrolment started in
January 2011 and was completed in March 2013.
Participants were seen every month for the first 3 months
and three-monthly thereafter, and were followed for 12
months to 3.5 years, depending on date of enrolment. At
each visit, adherence to trial drug, ARTand ITN use was
assessed, using a structured questionnaire and returned pill
counts (trial drug only). Participants were seen by a doctor
who assessed their health, treated any concurrent
infections, and dispensed trial drug. Participants were
issued with a supply of trial drug to last until their next
scheduled visit, along with a 3 day/month buffer stock in
case they were late. Blood samples were drawn at
scheduled visits for a malaria slide, CD4þ cell count,
and full blood count. Participants were encouraged to
attend the study clinic if unwell. If the participant was
suspected to have malaria, based on a history of malaria
associated symptoms (reported fever, headache, chills and
rigors, joint aches, muscles aches, vomiting or diarrhoea),
a blood slide and other tests deemed necessary were done,
and confirmed malaria was treated with arthemeter-
lumefantrine according to national guidelines [19].
Participants who reported having been treated for malaria
elsewhere (e.g. during a journey) were asked to present
documentary evidence of diagnoses and test results.
Participants were withdrawn from trial medication and
started on open-label CTX if their CD4þ cell count fell
below 250 cells/ml at any point during the trial.
Laboratory methods
A blood sample was used to prepare thick and thin films
on a glass slide. Specimens were processed using
Leishman’s stain and examined by microscopy. Thick
film specimens were used to record the number of
636 AIDS 2016, Vol 30 No 4
parasites per 200 white blood cells and thin films to
identify the plasmodium species.
For this study we considered two categories of malaria:
(1) clinical malaria, defined by the presence or history
(during the previous 2 weeks) of fever and microscopi-
cally confirmed malaria parasites;
(2) severe malaria (based on WHO guidelines [20]),
diagnosed if a patient had P. falciparum asexual
parasitemia, no other obvious cause of symptoms and
met any of the following criteria: convulsions, loss
of consciousness, hypotension (systolic blood pressure
<70 mmHg), admission to hospital due to malaria,
laboratory evidence of liver or kidney damage,
severe normocytic anaemia (haemoglobin <50 g/dl,
PCV<15%), or hyperparasitaemia on blood slide
(>5% or 250 000/ml).
Sample size
A total of 2180 participants were recruited and followed
for up to 3.5 years. The sample size for the main trial was
defined based on the power to demonstrate noninfer-
iority of placebo for the primary efficacy outcome of time
to the first CTX-preventable event or death [17,18]. For
this study, assuming an incidence of 1.4 clinical malaria
episodes/100 person-years (pyrs) in the control (CTX)
arm, as observed in a previous study among HIV positive
adults on ART in Uganda [21], and an average follow-up
of 2 years, we estimated that the COSTOP trial would
have more than 80% power to detect as significant (at the
5% level) a doubling of the incidence of clinical malaria in
participants who stopped CTX compared with those
who continued, assuming a 15% loss to follow-up at the
end of the study.
Statistical analysis
Data were double-entered and verified in MS Access and
analysed using Stata 12 (Stata Corp, College Station,
Texas, USA). All analyses used an intention-to-treat
(ITT) approach.
Baseline characteristics were compared between trial
arms. Socioeconomic status (SES) was measured by
combining data from all trial participants on housing
construction and ownership of household items into an
asset index score using principal component analysis [22].
Person years at risk were calculated from enrolment until
the date last seen or end of trial. After each malaria
episode, participants were considered to be not at risk for
another episode until the episode resolved (as evidenced
by resolution of symptoms and a negative repeat slide at
the 14-day follow-up visit), or for 28 days, if a resolution
date was not available. Time to first episode of clinical
malaria was examined using Kaplan–Meier plots, and
compared between trial arms using the log rank test. The
incidence of all clinical malaria episodes, the rate ratio for
the effect of trial arm, and 95%CI were estimated using
random effects Poisson regression to account for multiple
episodes within the same participant. The incidence of
severe malaria was calculated and compared between
arms.
In secondary analyses, follow-up time was divided into
12-month bands and analysis stratified by time to
investigate possible effect modification of trial arm with
time. Effect modification was assessed by comparing a
model with fixed effects for treatment arm and timeband
to one with treatment arm, timeband and their
interaction, using the likelihood ratio test. In addition,
effect modification by enrolment site was investigated.
The effect of trial drug adherence, and of ITN use, on
malaria was assessed. The proportion of expected doses of
trial drug taken, based on counts of returned pills at each
scheduled visit, was calculated as (tablets dispensed –
tablets returned)/(days elapsed since pills were dispensed).
We defined ‘good’ adherence as taking 80–105%
expected doses, allowing for adherence up to 105%
due to possible imprecision in tablet counts. Each
participant’s overall adherence was categorized as being
good at not less than 80% of visits or less than 80% of
visits. At each visit, participants were asked if they had
always slept under an ITN since their previous visit.
Overall ITN use was characterized as having always used
an ITN at not less than 90% of visits or less than 90%
of visits.
Ethical approval
Approval for the study was obtained from the Science and
Ethics Committee of the Uganda Virus Research
Institute, the Uganda National Council of Science and
Technology, the Ugandan National Drug Authority, and
the Ethics Committee of the London School of Hygiene
and Tropical Medicine.
Results
A total of 2180 participants were enrolled into the
COSTOP trial. Participants’ characteristics at baseline
were balanced by trial arm (Table 1). Baseline charac-
teristics have been described previously [17]. Overall,
mean (SD) age was 41 [8] years; 74% of participants were
female; 70% had primary education or less; and 52% had a
CD4þ cell count below 500 cells/ml.
Although balanced by trial arm within each site, there
were some differences in participant characteristics
between the enrolment sites. Participants in Masaka
were slightly older, had lower levels of education, and
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were of lower SES than those in Entebbe (Table 1). They
also had higher CD4þ cell counts at enrolment, and had
been on ART for longer.
Follow-up
Participants were followed for a median of 2.53 years
(interquartile range¼ 1.86–2.76), with no evidence of a
difference between arms (CTX median 2.53; interquar-
tile range 1.96–2.76 years vs. placebo 2.53; 1.84–2.76
years; P¼ 0.66 by Wilcoxon rank-sum test). In total 1875
participants (943 CTX) completed follow-up (Fig. 1); 36
participants were withdrawn from trial drug (18 CTX)
and started on open-label CTX; 232 participants were
lost to follow-up (109 CTX); and 37 participants died
(19 CTX). Only one death was malaria related (CTX)
and was due to quinine toxicity. Overall, 13 043
scheduled visits were attended by participants on CTX
and 12 913 by those on placebo (Fig. 1).
Effect of stopping cotrimoxazole
There were 453 episodes of clinical malaria experienced
by 362 participants (range 1–5) during follow-up; 9% of
participants in the CTX arm and 24% of those in the
placebo arm had at least one episode of clinical malaria.
Time to the first clinical malaria event was significantly
shorter in the placebo arm than in the CTX arm (log rank
test P< 0.001) (Fig. 2).
The overall incidence of clinical malaria was 9.1
(95%CI¼ 8.2–10.1) episodes/100 pyrs. The incidence
of malaria was 3.5 times higher in participants on placebo
than on CTX (95%CI¼ 2.7–4.4; P< 0.001; Table 2).
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Kaplan-Meier failure estimates
Fig. 2. Time to occurrence of first malaria event by treat-
ment arm.
2933 number screened
2180 enrolled 
Reason for non-enrolment
•   Low CD4+ count    382 (51%)
•   Neutropenia         89 (12%)
•   Never returned     93 (12%)
•   Other                   189 (25)
Randomized to CTX 1089 Randomized to placebo 1091
932 (85%) completed follow up 
12193 visits made
350 (32.1%) had at least one 
malaria episode                     
943 (87%) completed follow up 
13043 visits made
103 (9.5%) had at least one 
malaria episode
Lost to follow up 109 (10.0%)
Stopped trial drug
Died 19 (1.7%)
18 (1.7%)
Lost to follow up
Stopped trial drug
Died
123 (11.3%)
18 (1.7%)
18 (1.7%)
Fig. 1. COSTOP trial profile.
There was some evidence that the effect of stopping CTX
on clinical malaria incidence decreased over time:
although incidence remained higher in the placebo
arm, the difference between arms was less in the third
year (rate ratio¼ 2.1; 95%CI¼ 1.3–3.5) than in the first
year (rate ratio¼ 3.6; 95%CI¼ 2.6–5.0; P for inter-
action¼ 0.10) (Table 2). In the placebo arm, clinical
malaria incidence decreased from 17.3/100 pyrs in the
first year to 9.0/100 pyrs after the second year (P for trend
<0.001; Supplementary Figure, http://links.lww.com/
QAD/A828). In the CTX arm, clinical malaria incidence
remained similar over time (rate ratio for linear trend in
incidence from one year to the next¼ 0.90, CI¼ 0.69–
1.16, P¼ 0.40).
The relative effect of stopping CTX on clinical malaria
was greater in Entebbe (rate ratio¼ 6.8; 95%CI¼ 4.1–
11.1) than in Masaka (rate ratio¼ 2.7; 95%CI¼ 2.1–3.6;
P for interaction <0.001) (Table 2). In both arms, the
incidence of clinical malaria was higher in Masaka than in
Entebbe (CTX: 6.3 vs. 1.6/100 pyrs, respectively;
placebo 17.2 vs. 10.6/100 pyrs, respectively).
Overall, 15 (2 CTX, 13 placebo) episodes of severe
malaria occurred among the 2180 participants (<1%)
(Table 2). None of the participants had more than one
episode of severe malaria. Reasons for classifying
malaria as severe were: high parasitemia [2], loss of
consciousness [1], mental confusion [1] and hospital
admission [11]. The overall incidence of severe malaria
was 0.30/100 pyrs (95%CI¼ 0.18–0.49); the incidence
of severe malaria was 6.5 (95%CI¼ 1.5–29.0) times
higher in the placebo arm than in the CTX arm. Only
one participant (CTX arm) died of a malaria-related
event.
The NNTwith CTX for one year to prevent one malaria
episode was 10, and was 233 for severe malaria.
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Table 2. Incidence of malaria by trial arm, follow-up time, trial site, adherence to trial drug and ITN use.
Trial arm Episodes Person-years
Rate/100 person-
years (95% CI)a Rate ratioa
P value (CTX
vs. placebo)
P value (for
interaction)b
Clinical malaria
CTX 103 2540 4.1 (3.3–5.0) 1 <0.001
Placebo 350 2515 14.1 (12.5–15.0) 3.5 (2.5–4.4)
Severe malariac,d
CTX 2 2543 0.08 (0.02–0.31) 1 0.004
Placebo 13 2524 0.52 (0.30–0.89) 6.55 (1.48–29.01)
Stratified analyses
Stratum variable
Follow-up time
1st year CTX 51 1065 4.8 (3.6–6.3) 1 <0.001 0.097
Placebo 183 1062 17.3 (14.8–20.2) 3.6 (2.6–5.0)
2nd year CTX 29 939 3.1 (2.1–4.5) 1 <0.001
Placebo 120 924 13.1 (10.8–15.8) 4.2 (2.8–6.4)
After 2nd year CTX 23 536 4.3 (2.8–6.5) 1 0.004
Placebo 47 528 9.0 (6.7–12.1) 2.1 (1.3–3.5)
Site
Entebbe CTX 19 1215 1.6 (1.0–2.5) 1 <0.001 <0.001
Placebo 127 1209 10.6 (8.8–12.8) 6.8 (4.1–11.1)
Masaka CTX 84 1325 6.3 (5.1–7.9) 1 <0.001
Placebo 223 1306 17.2 (14.8–20.0) 2.7 (2.1–3.6)
Trial drug adherence
Good adherence at
80% of visitse,f CTX 57 1724 3.3 (2.5–4.4) 1 0.01 0.25
<80% of visitse,f CTX 46 816 5.6 (4.1–7.6) 1.7 (1.1–2.6)
80% of visitse,g Placebo 205 1617 12.8 (12.0–14.9) 1 0.05
<80% of visitse,g Placebo 145 897 16.4 (13.6–19.8) 1.3 (1.0–1.6)
ITN use
Reported always using ITN at
90% of visits CTX 86 2124 4.1 (3.3–5.1) 1 P¼0.98 0.39
<90% off visits CTX 17 416 4.1 (2.5–6.7) 1.0 (0.6–1.7)
90% of visits Placebo 267 2038 13.3 (11.6–15.2) 1 P¼0.06
<90% off visits Placebo 83 476 17.5 (13.6–22.5) 1.3 (1.0–1.8)
CTX, cotrimoxazole; ITN, insecticide-treated bed net.
arates and rate ratios adjusted for clustering of multiple episodes within participant using random effects Poisson regression.
bP value for interaction between stratum variable with treatment arm.
cP. falciparum malaria with clinical or laboratory features of severity.
dRates and rate ratios from Poisson regression without adjustment for clustering since no participant had more than one episode.
e‘Good’ adherence defined as 80–105% of expected tablets taken, based on pill counts.
fRate ratio and P value for comparison in CTX arm.
gRate ratio and P value for comparison in placebo arm.
Effect of adherence to trial drug and insecticide-
treated bed net use on malaria
Among participants on CTX, the incidence of clinical
malaria in those with good adherence at less than 80% of
visits was 1.7 (95%CI¼ 1.1–2.6) times higher than in
those with good adherence at not less than 80% of visits
(P¼ 0.01) (Table 2). Among participants on placebo,
malaria incidence was 1.3 (95%CI¼ 1.0–1.6) times
higher in those with good adherence at less than 80% of
visits (P¼ 0.05). The relative outcome of effect of
stopping CTX was greater in participants with good
adherence than in those with lower adherence (rate
ratio¼ 3.9, 95%CI¼ 2.8–5.3 vs. rate ratio¼ 2.9,
95%CI¼ 2.0–4.2).
Malaria incidence did not differ by reported ITN
use among participants on CTX (rate ratio¼ 1.0;
95%CI¼ 0.6–1.7; P¼ 0.98). However, malaria inci-
dence was higher in participants on placebo who reported
using an ITN at less than 90% of visits than in those who
reported ITN use at not less than 90% of visits
(rate ratio¼ 1.3, 95%CI¼ 1.0–1.8; P¼ 0.06), although
there was no evidence of significant effect modification
by treatment arm (P¼ 0.39).
Discussion
In this trial, participants on ART who stopped
prophylactic CTX had a 3.5-fold higher probability to
experience clinical malaria than those who continued.
This is expected given the antimalarial properties of CTX
[23] and is consistent with other studies in adults on ART
who discontinued CTX [21,24–28]. However the rate
ratio in our study was much smaller than reported by
other randomized trials in adults. Campbell et al. [21]
conducted an open-label, cluster (household) RCT in
Uganda to investigate the effect of stopping CTX on the
incidence of malaria and diarrhoea among HIV-infected
adults on ART with CD4þ above 200 cells/ml. The trial
enrolled 836 participants with median time on ART of
3.7 years and found that participants stopping CTX had a
32.5-fold (8.6–275.0) higher malaria incidence than
those that continued. The trial was stopped after
4 months. Polyak et al. [28] conducted an open-label
RCT comparing stopping versus continuing CTX
prophylaxis among 500 HIV-infected adults in western
Kenya who had been on ART for more than 18 months.
After a year of follow-up participants stopping CTX had
a 33.2-fold (95%CI¼ 4.5–241.0) higher malaria inci-
dence than those who continued CTX.
The contrasting results between these trials and ours
could have resulted from the shorter follow-up times
(4 months and 1 year in the Campbell and Polyak studies,
respectively) and from the smaller number of malaria
episodes (55 and 34, respectively) compared with our
study, in which 453 episodes of clinical malaria were
documented over a median follow-up time of 2.5 years.
Another explanation could be that participants in our trial
may have used CTX from other sources outside the trial,
which may have accounted for the smaller differences
between arms. However, exit interviews conducted at the
end of our trial did not find any evidence that participants
had taken CTX from other sources. We used an ITT
approach to the analysis; however, only 18 participants in
the placebo arm were withdrawn from trial medication
and started on open-label CTX, so this is unlikely to have
had a large impact on our results. Importantly, the
Campbell and Polyak studies were not blinded, so that
investigators or participants might have been more likely
to investigate or seek treatment if they felt that stopping
CTX might be risky. This source of potential observer
bias may have resulted in diagnosing malaria more
frequently in participants who had stopped CTX.
Although the incidence of severe malaria was higher in
the placebo arm, there was very little severe malaria in our
trial (only 1.2% of participants in the placebo arm) and
there was no statistical difference in overall number of
deaths (due to any cause) between trial arms. This is
consistent with findings in the study by Campbell et al.
[21]. Only one malaria-related death was recorded, and
this occurred in the CTX arm.
We found a marked decrease in malaria incidence over
time in the placebo arm whereas the incidence in the
CTX arm remained stable. This initially higher incidence
among participants who had stopped CTX could be a
consequence of the detrimental effects that HIV had
caused on the innate immune response to malaria and
other infections [29]. Whilst participants with low
immunity were initially protected against malaria due
to CTX, it is possible that the incidence of malaria
increased when CTX was discontinued, until participants
re-acquired some immunity against malaria. This has
been described among children [30].
As expected, participants with good adherence to
trial drug in the CTX arm had less malaria than those
whose adherence was not as good. Unexpectedly, good
adherence was also associated with reduced malaria
incidence in the placebo arm. A possible explanation is
that participants with suboptimal adherence to trial drug
might also be less likely to adhere to other malaria
prevention measures like ITN use. There was no
association of reported ITN use with malaria in the
CTX arm. In contrast, participants on placebo with
high reported ITN use had less malaria than those with
lower reported ITN use, suggesting that people who
discontinue CTX would benefit from general malaria
prevention measures.
There were fewer malaria episodes observed in partici-
pants at Entebbe than Masaka, in both trial arms and over
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time. Participants at Entebbe were generally younger, and
had attained a higher education level and SES compared
with those in Masaka. If participants in Entebbe were
better able to take care of themselves, had better housing
or could access treatment more easily this may have
resulted in a lower incidence of malaria at the Entebbe
site. Another possible explanation is that malaria
endemicity and therefore exposure to malaria was higher
in Masaka compared with Entebbe. Data on malaria
endemicity by region in Uganda are limited; however,
both areas are considered to have very high malaria
endemicity [31]. Recent reports for the three quarters up
to June 2015 showed an incidence of 101, 59, and 106 per
1000 population in Masaka district, and 82, 86 and 56 in
Wakiso district, which includes Entebbe [32]. This seems
to suggest that background exposure to malaria may be
higher in Masaka.
Strengths and limitations
Strengths of our study include its design as a double-blind
placebo-controlled randomized trial, its large sample size,
and that participants were seen at frequent scheduled visits
and sick visits at which screening for malaria was routinely
performed and adherence to trial drug and ARTassessed.
Furthermore, participant retention was high, with more
than 85% completing follow-up.
Unfortunately we do not have data on malaria incidence
from HIV-negative individuals in our study area. We
can therefore not determine the extent to which the
incidence of malaria among HIV-infected participants on
ART and CTX may have been reduced below normal
levels.
Conclusion
In this blinded placebo-controlled trial in Uganda,
participants who were stable on ART and stopped taking
prophylactic CTX had malaria more frequently and
severely than those who continued, but the difference was
less than has been reported by earlier studies. Malaria
incidence reduced in participants on placebo over time.
Few participants experienced severe malaria. A potential
decision to stop or continue CTX will have to take into
account the main COSTOP trial results that have shown a
clear benefit of continued CTX prophylaxis in preventing
bacterial infections, but also showed an increase in
neutropenia incidence and no reduction in overall
mortality [17]. The NNT to prevent one CTX-
preventable event or malaria is also worth considering.
According to current WHO guidelines CTX may be
discontinued in some situations, but should be continued
in countries with high endemicity of malaria and bacterial
infections [15]. Given the costs and toxicity of CTX and
the potential development of wide spread of CTX
resistance, further research will be useful in identifying
groups and circumstances in which CTX prophylaxis
could be safely stopped.
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